tbuckley/cabot-search huggingface dataset:
Breast Cancer Recurrences at the Chest Wall (BCRCW) When Standard Treatments (TX) Have Failed: Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) + Mild Local Hyperthermia (MLH)
Authors: H.S. Rugo, S.C. Formenti, R.J. Myerson, C.J. Diederich, B.M. O'Connor, A.J. Matzkowitz, F. Muggia
Journal: Annals of Oncology (2012)
The 12-Gene Colon Cancer Recurrence Score (RS) Predicts Recurrence in Stage II and III Colon Cancer Patients Treated with 5FU/LV (FU) and 5FU/LV + Oxaliplatin (FU + OX): Validation in NSABP C07
Authors: M.J. O'Connell, M. Lee, M. Lopatin, G. Yothers, K.M. Clark-Langone, C. Millward, S. Paik, S. Sharif, S. Shak, N. Wolmark
Journal: Annals of Oncology (2012)
Trends in Total Binge Drinks per Adult Who Reported Binge Drinking — United States, 2011–2017
Authors: Dafna Kanny, Timothy S. Naimi, Yong Liu, Robert D. Brewer
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Each year, excessive drinking accounts for one in 10 deaths among U.S. adults aged 20-64 years (1), and approximately 90% of adults who report excessive drinking* binge drink (i.e., consume five or more drinks for men or four or more drinks for women on a single occasion) (2). In 2015, 17.1% of U.S. adults aged ≥18 years reported binge drinking approximately once a week and consumed an average of seven drinks per binge drinking episode, resulting in 17.5 billion total binge drinks, or 467 total binge drinks per adult who reported binge drinking (3). CDC analyzed 2011-2017 Behavioral Risk Factor Surveillance System (BRFSS) data to assess trends in total annual binge drinks per adult who reported binge drinking in the United States overall and in the individual states. The age-adjusted† total annual number of binge drinks per adult who reported binge drinking increased significantly from 472 in 2011 to 529 in 2017. Total annual binge drinks per adult who reported binge drinking also increased significantly from 2011 to 2017 among those aged 35-44 years (26.7%, from 468 to 593) and 45-64 years (23.1%, from 428 to 527). The largest percentage increases in total binge drinks per adult who reported binge drinking during this period were observed among those without a high school diploma (45.8%) and those with household incomes <$25,000 (23.9%). Strategies recommended by the Community Preventive Services Task Force§ for reducing excessive drinking (e.g., regulating alcohol outlet density) might reduce binge drinking and related health risks.
A Phase II Study of Erlotinib as First-Line Treatment in Japanese Advanced NSCLC Patients Harboring EGFR Mutations
Authors: A. Horiike, M. Nishio, K. Goto, N. Yamamoto, K. Chikamori, M. Maemondo, T. Hida, N. Katakami, T. Tamura
Journal: Annals of Oncology (2012)
Impact of Enzalutamide, An Androgen Receptor Signaling Inhibitor, on Time to First Skeletal Related Event (SRE) and Pain in the Phase 3 Affirm Study
Authors: K. Fizazi, H.I. Scher, F. Saad, C.N. Sternberg, K. Miller, P. Mulders, K. Chi, E. Basch, M. Hirmand, J.S. de Bono
Journal: Annals of Oncology (2012)
HSA-MIR31-3P Expression as a Predictor of Anti-Egfr Response in Wild-Type Kras Patients with Metastatic Colorectal Cancer
Authors: P. Laurent-Puig, G. Manceau, J. Bachet, B. Chibaudel, F. Liebaert, O. Bouché, F. Penault-Llorca, M.D. Diebold, T. André, S. Imbeaud
Journal: Annals of Oncology (2012)
Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia
Authors: Lu Tang, Jianghua Wu, Cheng-Gong Li, Hui-Wen Jiang, Min Xu, Mengyi Du, Zhinan Yin, Heng Mei, Yu Hu
Journal: Clinical Cancer Research (2020)

This study aims to provide comprehensive insights into longitudinal immune landscape in acute myeloid leukemia (AML) development and treatment, which may contribute to predict prognosis and guide clinical decisions.Periphery blood samples from 79 patients with AML (at diagnosis or/and after chemotherapy or at relapse) and 24 healthy controls were prospectively collected. We performed phenotypic and functional analysis of various lymphocytes through multiparametric flow cytometry and investigated prognostic immune-related risk factors.Immune defects in AML were reflected in T and natural killer (NK) cells, whereas B-cell function remained unaffected. Both CD8+ T and CD4+ T cells exhibited features of senescence and exhaustion at diagnosis. NK dysfunction was supported by excessive maturation and downregulation of NKG2D and NKP30. Diseased γδ T cells demonstrated a highly activated or even exhausted state through PD-1 upregulation and NKG2D downregulation. Effective therapeutic response following chemotherapy correlated with T and NK function restoration. Refractory and relapsed patients demonstrated even worse immune impairments, and selective immune signatures apparently correlated clinical outcomes and survival. PD-1 expression in CD8+ T cells was independently predictive of poor overall survival and event-free survival.T-cell senescence and exhaustion, together with impaired NK and γδ T-cell function, are dominant aspects involved in immune dysfunction in AML. Noninvasive immune testing of blood samples could be applied to predict therapeutic reactivity, high risk for relapse, and unfavorable prognosis.
Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis—Report 1
Authors: Rupesh Agrawal, Ilaria Testi, Sarakshi Mahajan, Yew Sen Yuen, Aniruddha Agarwal, Onn Min Kon, Talin Barisani-Asenbauer, John H. Kempen, Amod Gupta, Douglas A. Jabs, Justine R. Smith, Quan Dong Nguyen, Carlos Pavesio, Vishali Gupta, Mamta Agarwal, Manisha Agarwal, Ashutosh Aggarwal, Kanika Aggarwal, Mukesh Agrawal, Hassan Al-Dhibi, Sofia Androudi, Fatma Asyari, Manohar Babu Balasundaram, Kalpana Babu Murthy, Edoardo Baglivo, Alay Banker, Reema Bansal, Soumyava Basu, Digamber Behera, Jyotirmay Biswas, Bahram Bodaghi, Ester Carreño, Laure Caspers, Soon Phaik Chee, Romi Chhabra, Luca Cimino, Luz Elena Concha del Rio, Emmett T. Cunningham, Andrè Luiz Land Curi, Dipankar Das, Janet Davis, Marc DeSmet, Ekaterina Denisova, Alastair K. Denniston, Marie-Hélène Errera, Alejandro Fonollosa, Amala George, Debra A. Goldstein, Yan Guex Crosier, Dinesh Visva Gunasekeran, Avinash Gurbaxani, Alessandro Invernizzi, Hazlita M. Isa, Shah Md. Islam, Nicholas Jones, Deeksha Katoch, Moncef Khairallah, Amit Khosla, Michal Kramer, Amitabh Kumar, Atul Kumar, Rina La Distia Nora, Richard Lee, Careen Lowder, Saurabh Luthra, Padmamalini Mahendradas, Dorine Makhoul, Shahana Mazumdar, Peter McCluskey, Salil Mehta, Elisabetta Miserocchi, Manabu Mochizuki, Oli S. Mohamed, Cristina Muccioli, Marion R. Munk, Somasheila Murthy, Shishir Narain, Heloisa Nascimento, Piergiorgio Neri, Myhanh Nguyen, Annabelle A. Okada, Pinar Ozdal, Alan Palestine, Francesco Pichi, Dhananjay Raje, S.R. Rathinam, Andres Rousselot, Ariel Schlaen, Shobha Sehgal, H. Nida Sen, Aman Sharma, Kusum Sharma, Samir S. Shoughy, Nirbhai Singh, Ramandeep Singh, Masoud Soheilian, Sudharshan Sridharan, Jennifer E. Thorne, Christoph Tappeiner, Stephen Teoh, Maria Sofia Tognon, Ilknur Tugal-Tutkun, Mudit Tyagi, Harvey Uy, Daniel Vitor Vasconcelos Santos, Natasa Vidovic Valentincic, Mark Westcott, Ryoji Yanai, Bety Yanez Alvarez, Rahman Zahedur, Manfred Zierhut
Journal: Ophthalmology (2020)
Relationship Between Intestinal Function and Exposure to Sorafenib and Sunitinib in Cancer Patients
Authors: J. Durand, B. Blanchet, M. Buyse, N. Neveux, P. Boudou-Rouquette, O. Mir, M. Vidal, L. Cynober, F. Goldwasser
Journal: Annals of Oncology (2012)
P-0269 Circulating Endothelial Cells in Patients with Colorectal Cancer: Flow Cytometry Analysis of Cell Markers CD146-PE and CD45-FITC
Authors: Franco Lumachi, Paolo Doretto, Renato Tozzoli, Davide Santeufemia, Giordano Chiara, Stefano Basso
Journal: Annals of Oncology (2012)
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)
Authors: Ho Sup Lee, Kihyun Kim, Seok Jin Kim, Je‐Jung Lee, Inho Kim, Jin Seok Kim, Hyeon‐Seok Eom, Dok Hyun Yoon, Cheolwon Suh, Ho‐Jin Shin, Yeung‐Chul Mun, Min Kyoung Kim, Sung‐Nam Lim, Chul Won Choi, Hye Jin Kang, Sung‐Soo Yoon, Chang‐Ki Min
Journal: American Journal of Hematology (2020)

Patients with transplant-ineligible relapsed and refractory multiple myeloma (RRMM) have a short life expectancy, especially when they have failed both the proteasome inhibitor and immunomodulator therapies. This study aimed to assess the efficacy and safety of pomalidomide, cyclophosphamide, and dexamethasone (PCd) in elderly patients with RRMM. This phase 2 clinical trial recruited 55 elderly patients with RRMM. The patients underwent a 28-day treatment cycle: pomalidomide (4 mg/day on days 1-21, administered orally) and cyclophosphamide (400 mg/day on days 1, 8, and 15; administered orally) plus dexamethasone. The median (range) age of the patients was 73.3 (64-86) years, and 8 (14.5%) patients who were ≥ 80 years old. Eight (14.5%) and 31 (56.4%) patients exhibited stage III (revised international staging system) and frail status (simplified frailty scale), respectively. The overall response rate (ORR) and clinical benefit rate (CBR) of PCd therapy were 58.2% and 72.7%, respectively. The median PFS and median overall survival (OS) were 6.90 months (95% CI, 4.7-9.0) and 18.48 months (95% CI, 9.4-27.6), respectively. The incidence rate of grade ≥ 3 non-hematological toxicities was 70.8%. In particular, the incidence rate of primary infection was 45.4%, including 21.8% for pneumonia, 9.0% for sepsis, and 14.6% for febrile neutropenia. In conclusion, PCd is an effective regimen for elderly patients with RRMM who had failed both bortezomib and lenalidomide treatments, but in whom the treatment-associated infection is the main cause of morbidity and mortality.
Microrna Profiling and CDDP-GPG DNA Adduct Formation Analysis in a Panel of Cisplatin Resistant Non-Small Cell Lung Cancer Cell Lines
Authors: M. Barr, S.G. Gray, D.A. Fennell, J.J. O'Leary, D. Richard, J. Thomale, A.C. Hoffmann, K.J. O'Byrne
Journal: Annals of Oncology (2012)
Cost-Effectiveness of Primary Pegfilgrastim Prophylaxis in Breast Cancer Patients at Risk of Febrile Neutropenia
Authors: M.J. Aarts, J.P. Grutters, F.P. Peters, C.M. Mandigers, M.W. Dercksen, J.M. Stouthard, J.W. Nortier, H.W. van Laarhoven, L.J. van Warmerdam, V.C. Tjan-Heijnen
Journal: Annals of Oncology (2012)
Predictive Value of Time to Best Response for Efficacy MTOR Inhibitors (MTORI) in Metastatic Renal Cell Carcinoma (MRCC) Patients (PTS)
Authors: R.T. Elaidi, C. Teghom, A. Comte, M. Jebali, J. Fouque, J. Medioni, S. Oudard
Journal: Annals of Oncology (2012)
Liver Resectability Following MFOLFOX6 with Bevacizumab as the First-Line Treatment of Unresectable Liver Limited Metastases from Colorectal Cancer in Japanese Patients (KSCC 0802)
Authors: Y. Akagi, T. Beppu, Y. Emi, Y. Kakechi, H. Saeki, E. Oki, F. Fujita, M. Inomata, T. Sawai, H. Samura, H. Baba, S. Natsugoe, Y. Ogata, S. Tokunaga, Y. Maehara
Journal: Annals of Oncology (2012)
EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles
Authors: Guillaume Bort, François Lux, Sandrine Dufort, Yannick Crémillieux, Camille Verry, Olivier Tillement
Journal: Theranostics (2020)

Interest of tumor targeting through EPR effect is still controversial due to intrinsic low targeting efficacy and rare translation to human cancers. Moreover, due to different reasons, it has generally been described for relatively large nanoparticles (NPs) (hydrodynamic diameter > 10 nm). In this review EPR effect will be discussed for ultrasmall NPs using the example of the AGuIX® NP (Activation and Guiding of Irradiation by X-ray) recently translated in clinic. AGuIX® NP is a 4 ± 2 nm hydrodynamic diameter polysiloxane based NP. Since AGuIX® NP biodistribution is monitored by magnetic resonance imaging (MRI) and its activation is triggered by irradiation upon X-rays, this NP is well adapted for a theranostic approach of radiotherapy cancer treatment. Here we show that AGuIX® NP is particularly well suited to benefit from EPR-mediated tumor targeting thanks to an ultrasmall size and efficacy under irradiation at small dose. Indeed, intravenously-injected AGuIX® NP into rodent cancer models passively reached the tumor and revealed no toxicity, favoured by renal clearance. Moreover, translation of AGuIX® NP accumulation and retention into humans carrying brain metastases was validated during a first-in-man phase Ib trial taking advantage of easy biodistribution monitoring by MRI.
Cisplatin + Vinorelbine (DDP + VNB) Administered in 60 Cases of Recurrent/Metastatic Salivary Gland Malignancies (RMSGM): Final Report
Authors: O. Ostellino, M. Airoldi, M. Garzaro, F. Pedani, L. Raimondo, G. Riva, S. Carnio, G. Pecorari, G. Fora, C. Giordano
Journal: Annals of Oncology (2012)
P3.02 Challenges in The Implementation of a Translational Research Biopsy-Driven Trial to Study Drug Resistance in Triple Negative Breast Cancer Patients
Authors: A. Aguilar-Mahecha, J. Lafleur, C. Seguin, M. Rosenbloom, E. Przybytkowski, M. Pelmus, Z. Diaz, G. Batist, M. Basik
Journal: Annals of Oncology (2012)
Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain
Authors: Liron L. Israel, Anna Galstyan, Eggehard Holler, Julia Y. Ljubimova
Journal: Journal of Controlled Release (2020)

Magnetic nanoparticles in general, and iron oxide nanoparticles in particular, have been studied extensively during the past 20 years for numerous biomedical applications. The main applications of these nanoparticles are in magnetic resonance imaging (MRI), magnetic targeting, gene and drug delivery, magnetic hyperthermia for tumor treatment, and manipulation of the immune system by macrophage polarization for cancer treatment. Recently, considerable attention has been paid to magnetic particle imaging (MPI) because of its better sensitivity compared to MRI. In recent years, MRI and MPI have been combined as a dual or multimodal imaging method to enhance the signal in the brain for the early detection and treatment of brain pathologies. Because magnetic and iron oxide nanoparticles are so diverse and can be used in multiple applications such as imaging or therapy, they have attractive features for brain delivery. However, the greatest limitations for the use of MRI/MPI for imaging and treatment are in brain delivery, with one of these limitations being the brain-blood barrier (BBB). This review addresses the current status, chemical compositions, advantages and disadvantages, toxicity and most importantly the future directions for the delivery of iron oxide based substances across the blood-brain barrier for targeting, imaging and therapy of primary and metastatic tumors of the brain.
Molecular Genotyping with High-Throughput Method, Oncomap V4.0 for Small Biopsy Samples in Newly Diagnosed Advanced Non-Small Cell Lung Cancer Patients
Authors: C.H. Maeng, M.A. Ahn, K. Park, S.J. Lee, H.A. Jung, W. Chang, S. Park, M.K. Choi, Y.S. Kim, J.Y. Hong
Journal: Annals of Oncology (2012)
Prevalence of autoimmune conditions in patients with marginal zone lymphoma: Exploratory analysis of a series of consecutive patients.
Authors: Joanna Grabska, Bruno Bockorny, Ion Codreanu, Prerna Mewawalla, Constantin Dasanu, Joel Silver
Journal: Journal of Clinical Oncology (2012)

e18543 Background: Recent literature suggests that an association exists between marginal zone lymphoma (MZL) and certain autoimmune conditions. Furthermore, MZL and autoimmune diseases may share same pathogenesis in these patients. The present study was set to identify the prevalence of autoimmune phenomena in MZL patients and compare it with same in general population. Methods: We conducted both retrospective and prospective analyses in a series of consecutive patients (n=24) with MZL that had been followed in outpatient setting. Median age was 71.8 years (range, 50-96). Records were reviewed for the presence of autoimmune abnormalities; length of the prospective analysis segment was ~24 months. Prevalence of autoimmune disorders in our cohort was compared to their respective prevalence in general population. Statistical analysis: The obtained values were tested for statistical significance using Fisher’s exact test for small number of observations (95% confidence); a p-value &lt; 0.05 was considered significant. Results: A total of 50% patients included in our study had documented autoimmune conditions. Identified autoimmune disorders included Hashimoto thyroiditis (n=5), immune thrombocytopenia [ITP] (n=4), rheumatoid arthritis [RA] (n=1), Raynaud's phenomena (n=1), psoriasis (n=1), and autoimmune hemolytic anemia [AIHA] (n=1). Statistical analysis showed the following significance: Hashimoto thyroiditis (p=0.037), ITP (p&lt;0.01), AIHA (p&lt;0.01), RA(p=0.351), psoriasis (p=0.479), and Raynaud's phenomena (p=0.666). Conclusions: Circa half of MZL patients also have autoimmune conditions, thus significantly exceeding the overall prevalence in general population. Statistically significant differences in our MZL patients were recorded for Hashimoto thyroiditis, ITP, and AIHA. When compared to the prevalence in general population, the difference did not reach statistical significance for RA, psoriasis, and Raynaud's phenomena. However, this may be related to the relatively small size of the analyzed cohort. Therefore, larger studies would be useful before definitive conclusions can be drawn.
Bullous pemphigoid after anti–programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes
Authors: Caroline A. Nelson, Sean Singer, Tianqi Chen, Ashleigh Eberly Puleo, Christine G. Lian, Erin X. Wei, Anita Giobbie-Hurder, Arash Mostaghimi, Nicole R. LeBoeuf
Journal: Journal of the American Academy of Dermatology (2020)
A Phase IB Combination Study of RO4929097 (RO), A Gamma-Secretase Inhibitor, and Temsirolimus (TEM) in Patients (PTS) with Advanced Solid Tumors
Authors: I. Diaz-Padilla, S.J. Hotte, S.P. Ivy, A.M. Oza, H.W. Hirte, A.R.A. Razak, E.X. Chen, I. Brana Garcia, L. Siu, P. Bedard
Journal: Annals of Oncology (2012)
Cardiac Toxicities after Treatment of Primary Hodgkin’s Lymphoma (HL). Analysis of the LENT-SOMA Questionnaire Registered in the Database of the German Hodgkin Study Group (GHSG).
Authors: Karolin Behringer, Gilman Elena, Lihovac Anesa, Nogova Lucia, Seegenschmiedt M. Heinrich, Diehl Volker, Engert Andreas
Journal: Blood (2005)
Serum Chromogranin a in Metastatic Carcinoma Prostate - a Prognostic Marker for Hormonal Therapy
Authors: G.S. Bhattacharyya, H. Malhotra, P.M. Parikh, J.K. Singh, G.B. Kanaka, S. Basu, M. Singh, J. Biswas, T. Shahid, A.A. Ranade
Journal: Annals of Oncology (2012)
Prevalence and disease predisposition of p.A91V perforin in an aged population of European ancestry
Authors: Ilia Voskoboinik, Paul Lacaze, Helena Sung-In Jang, Thijs Flinsenberg, Suran L. Fernando, Ian Kerridge, Moeen Riaz, Robert Sebra, Kevin Thia, Taherah Noori, Eric E. Schadt, John J. McNeil, Joseph A. Trapani
Journal: Blood (2020)
Bioinspired Biomaterials with a Brick‐and‐Mortar Microstructure Combining Mechanical and Biological Performance
Authors: Tian Li, Bing Ma, Jianmin Xue, Dong Zhai, Pengyu Zhao, Jiang Chang, Chengtie Wu
Journal: Advanced Healthcare Materials (2020)

The fabrication of bone regeneration biomaterials, which simultaneously possess superior mechanical performances and excellent bioactivity, remains challenging because these properties are usually mutually exclusive. Herein, inspired by the brick-and-mortar architecture of nacre, lamellar silicate-based bioceramic composites are successfully prepared by constructing orderly layered bioceramics infiltrated with a biomedical resin interlayer via the bidirectional freezing technique. The lamellar composites possess high strength and proper Young's moduli, which match with human cortical bone. Furthermore, the lamellar composites can release bioactive ions with a controlled profile, which significantly enhance the cell proliferation of both rabbit bone mesenchymal stem cells and periodontal ligament cells in vitro. Moreover, with the degradation of silicate bioceramics in vivo, newly formed bone tissue can grow into the materials to present the bioceramic/new bone/resin sandwich-like lamellar microstructure. The silicate-based bioceramic composites with brick-and-mortar architecture represent an excellent biomaterial in combination of superior mechanical performances matching that of human cortical bone, and excellent bioactivity for potential load-bearing bone regeneration.
Retrospective Analysis of Ifosfamide Encephalopathy in Patients with Bone and Soft Tissue Sarcomas
Authors: K. Takada, R. Takimoto, T. Yoshinaga, S. Iyama, K. Ono, K. Murase, T. Sato, K. Miyanishi, Y. Sato, M. Kobune, T. Soma, S. Nagoya, T. Yamashita, A. Watanabe, J. Kato
Journal: Annals of Oncology (2012)
Evaluation of Subcutaneous (SC) Versus Intravenous (IV) Palonosetron in Cancer Patients Treated with Platinum-Based Chemotherapy: A Randomized Pharmacokinetic Assay
Authors: E. Arevalo, A. Del Barrio, B. Sadaba, M.A. Campanero, J.R. Azanza, A. Gurpide, J.M. Lopez Picazo, S. Martin Algarra, J.L. Perez Gracia
Journal: Annals of Oncology (2012)
Investigation of a cyanine dye assay for the evaluation of the biocompatibility of magnesium alloys by direct and indirect methods
Authors: Afrah Al Hegy, Ryan Smith, Eric R. Gauthier, Joy E. Gray-Munro
Journal: Bioactive Materials (2020)

Magnesium and its alloys are promising candidates for a new generation of biodegradable metals in orthopaedic applications due to their excellent biocompatibility, biodegradability, and mechanical properties that are similar to natural bone. However, direct in vitro assessment of these materials in the presence of cells is complicated by degradation products from the alloy that lead to a false positive for the most commonly used cell adhesion and cell proliferation assays. In this paper, a cyanine dye was used to quantitatively evaluate the in vitro biocompatibility of a Mg AZ31 alloy by both direct and indirect methods. The cytotoxicity of the corrosion products was evaluated via an indirect method; a 25% decrease in cell viability compared to control samples was observed. Moreover, direct assessment of cell adhesion and proliferation showed a statistically significant increase in cell number at the surface after 72 h. In addition, the degradation rate and surface characteristics of the Mg AZ31 alloy were evaluated for both direct and indirect tests. The degradation rate was unaffected by the presence of cells while evidence of an increase in calcium phosphate deposition on the magnesium alloy surface in the presence of cells was observed. This study demonstrates that a cyanine dye based assay provides a more accurate assessment of the overall in vitro biocompatibility of biodegradable metals than the more commonly used assays reported in the literature to date.
The Merck Manual of Diagnosis and Therapy
Authors: J. W. HOLLINGSWORTH
Journal: JAMA (1978)

The<i>Merck Manual</i>began in 1899 as a guide to medical treatment and survives today in its 13th edition as a practical guide to diagnosis and therapy of nonsurgical problems. I remember the<i>Merck Manual</i>of medical school days (the 1940 edition) and am awestruck with the change. Memories from student days are poor, but I recall that edition as erroneous, loosely written, and, I believe, anonymous in authorship. The 13th edition, in contrast, was prepared by Dr Berkow with the aid of a distinguished 12-man editorial board and a stellar group of about 250 contributors. In undertaking to review this 2,000-page text of tightly written material, covering everything from ingrown toenail to the principles of cardiac surgery, I read completely the first 600 pages. This portion included many aspects of internal medicine, and I was pleased with what I found. The material, obviously prepared by many different authors, was